PBC stands for primary biliary cholangitis, a chronic liver disease in which the immune system gradually destroys the small bile ducts inside the liver. Bile normally flows through these ducts to help digest fats, but when the ducts are damaged, bile builds up in the liver and causes inflammation, scarring, and eventually cirrhosis if left untreated. PBC overwhelmingly affects women, who make up about 90% of cases, with female-to-male ratios ranging from 9:1 to as high as 22:1. Women typically present around age 54, while men tend to be diagnosed later, around age 68.
What Happens Inside the Liver
PBC is an autoimmune disease, meaning the body’s immune system mistakenly attacks its own tissue. In this case, the target is the cells lining the small bile ducts within the liver. The immune system loses tolerance to a specific protein found on the inner membranes of cells (a component of the energy-producing machinery inside every cell). Immune cells that react against this protein accumulate in the liver in large numbers.
The attack involves several types of immune cells working together. Certain white blood cells directly kill bile duct cells, while others produce inflammatory signals that amplify the damage and stimulate the production of autoantibodies. Clusters of immune cells, sometimes called tertiary lymphoid structures, form near the bile ducts and create an environment that sustains the autoimmune response. At the same time, a type of immune cell that normally keeps the immune system in check (regulatory T cells) is reduced in PBC patients, which allows the attack to continue unchecked.
In the early stages, the immune response is dominated by inflammation. As the disease progresses, a different set of immune signals takes over that promotes fibrosis, the buildup of scar tissue. This scarring is what eventually leads to cirrhosis and liver failure if the disease isn’t managed.
Symptoms and How PBC Feels
Many people with PBC have no symptoms at all when they’re first diagnosed. The disease is often caught through routine blood work that shows elevated liver enzymes, particularly alkaline phosphatase (ALP). When symptoms do appear, two stand out:
- Fatigue: Nearly all PBC patients develop moderate to severe fatigue over time. It’s one of the most disabling aspects of the disease, and it can persist even after a liver transplant, which suggests it isn’t caused by liver damage alone.
- Itching (pruritus): Affects roughly 20% to 70% of patients. The itching can be intense and widespread, often worse at night, and isn’t relieved by typical anti-itch creams. It’s caused by bile acids and other substances building up in the bloodstream.
Dry eyes and dry mouth are also common, as PBC frequently overlaps with Sjögren’s syndrome, another autoimmune condition. Some people develop darkening of the skin, small fatty deposits around the eyes, or joint pain. In advanced stages, jaundice (yellowing of the skin and eyes) signals significant bile buildup and worsening liver function.
How PBC Is Diagnosed
Diagnosis typically relies on a combination of blood tests rather than a liver biopsy. A doctor will look for at least two of the following three criteria: elevated ALP (at least 1.5 to 2 times the upper limit of normal), a positive test for antimitochondrial antibodies (AMA), and characteristic findings on biopsy if one is performed.
The AMA blood test is the most distinctive marker for PBC. Roughly 95% of people with PBC test positive for these antibodies, which target the same mitochondrial protein that the immune system attacks. In the small number of cases where AMA is negative, doctors can look for other PBC-specific antibodies to confirm the diagnosis. A liver biopsy isn’t always necessary but can help determine how much damage has already occurred.
First-Line Treatment
The cornerstone of PBC treatment is ursodeoxycholic acid (UDCA), a medication taken daily at a dose of 13 to 15 mg per kilogram of body weight. UDCA is a naturally occurring bile acid that protects liver cells, reduces the toxicity of the bile that accumulates, and slows disease progression. It’s recommended for all PBC patients with abnormal liver enzymes, regardless of how advanced the disease is.
Many patients respond well to UDCA, with improved blood work and slower progression to cirrhosis. However, up to 40% of patients don’t have an adequate response, which is defined by how much their liver enzyme levels improve after about a year of treatment. For these patients, additional therapies are now available.
Newer Treatment Options
Two newer medications received accelerated FDA approval in 2024 for patients who don’t respond well to UDCA or can’t tolerate it. Both work by activating receptors in the liver that help regulate bile acid production and reduce inflammation.
Elafibranor, approved in June 2024, showed strong results in clinical trials: 51% of treated patients met the key measure of improvement (normalized or significantly reduced ALP with normal bilirubin levels) compared to just 4% on placebo. Improvement appeared as early as four weeks. Seladelpar, approved in August 2024, performed similarly well, with over 60% of treated patients meeting the same benchmark versus 20% on placebo, and 25% achieving completely normal ALP levels.
Both medications still require confirmatory trials to prove they improve long-term outcomes like transplant-free survival, which is why they were granted accelerated rather than full approval. Those studies are currently underway.
Bone Health and Nutritional Concerns
PBC carries a significant risk of osteoporosis. About 30% of PBC patients have weakened bones, and that number climbs to 44% in people with advanced disease awaiting transplant. The connection involves several factors: chronic inflammation, reduced absorption of fat-soluble vitamins (particularly vitamin D and vitamin K), and the effects of bile acid buildup on bone metabolism.
Bone density testing is recommended for all PBC patients at the time of diagnosis. If results are normal, repeat testing every two to three years is standard. People with additional risk factors, such as severe cholestasis, low body weight, early menopause, or smoking, should be screened annually. Blood levels of calcium, phosphorus, vitamin D, and parathyroid hormone should also be checked at diagnosis and yearly after that, since impaired bile flow can reduce the absorption of fat-soluble vitamins from food.
Long-Term Outlook
The prognosis for PBC has improved dramatically since UDCA became widely used. Patients who respond well to treatment can have a near-normal life expectancy. Doctors assess treatment response after about one year by checking several routine blood markers, including bilirubin, ALP, albumin, and platelet count, along with the patient’s age. These values feed into scoring systems that predict long-term, transplant-free survival.
For patients who don’t respond to any available therapy and progress to end-stage liver disease, liver transplantation remains an option. PBC can recur in the transplanted liver, but this typically happens slowly and rarely leads to graft failure. The bigger challenge for many patients is managing quality of life, particularly the fatigue and itching that can persist regardless of how well the underlying liver disease is controlled.